Clinical Trial Update: Study of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type A [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 study evaluating ORGN001 (formerly ALXN1101) in neonates, infants, and children with Molybdenum Cofactor Deficiency Type A has completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Molybdenum Cofactor Deficiency Type

Drugs mentioned

• ALXN1101 (ALXN1101)
• ORGN001 (ORGN001)

Snippet

Sponsor: Origin Biosciences | Conditions: Molybdenum Cofactor Deficiency, Type A | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2023-10-17